Insmed (NASDAQ: INSM) and GW Pharmaceuticals PLC- (NASDAQ:GWPH) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.
This is a summary of recent ratings for Insmed and GW Pharmaceuticals PLC-, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|GW Pharmaceuticals PLC-||0||1||6||0||2.86|
Insider and Institutional Ownership
93.4% of Insmed shares are owned by institutional investors. Comparatively, 74.8% of GW Pharmaceuticals PLC- shares are owned by institutional investors. 5.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Insmed and GW Pharmaceuticals PLC-‘s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|GW Pharmaceuticals PLC-||$11.00 million||328.54||-$166.90 million||($8.88)||-14.66|
GW Pharmaceuticals PLC- has higher revenue and earnings than Insmed. GW Pharmaceuticals PLC- is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.
This table compares Insmed and GW Pharmaceuticals PLC-‘s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|GW Pharmaceuticals PLC-||-1,357.98%||-46.94%||-41.00%|
Risk and Volatility
Insmed has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, GW Pharmaceuticals PLC- has a beta of 2.5, meaning that its stock price is 150% more volatile than the S&P 500.
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC). Its earlier-stage pipeline includes preclinical compounds that the Company is evaluating in multiple rare diseases of unmet medical need, including methicillin-resistant staph aureus and NTM. Its earlier clinical-stage pipeline includes INS1007 and INS1009. INS1007 is an oral, reversible inhibitor of dipeptidyl peptidase 1. INS1009 is an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. It has completed a Phase I study of INS1009.
About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company’s commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.